RecruitingNCT06451393

Predicting Gastric Cancer Response to Chemo With Multimodal AI Model

A Radio-Pathomic Multimodal Machine Learning Model for Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Advanced Gastric Cancer: A Retrospective Observational Study

Sponsor

Sixth Affiliated Hospital, Sun Yat-sen University

Enrollment

500 participants

Start Date

Feb 1, 2013

Study Type

OBSERVATIONAL

Conditions

Gastric Cancer Chemotherapy Effect

Summary

This study aims to develop a multimodal model combining radiomic and pathomic features to predict pathological complete response (pCR) in advanced gastric cancer patients undergoing neoadjuvant chemotherapy (NAC). The researchers intended to collected pre-intervention CT images and pathological slides from patients, extract radiomic and pathomic features, and build a prediction model using machine learning algorithms. The model will be validated using a separate cohort of patients. This research intend to build a radiomic-pathomic model that can outperform models based on either radiomic or pathomic features alone, aiming to improve the prediction of pCR in gastric cancer.

Eligibility

Min Age: 20 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This study uses artificial intelligence (AI) to analyze CT scans, stomach scope images, and biopsy samples to predict how well a stomach cancer patient will respond to chemotherapy before surgery. The goal is to help doctors personalize treatment plans more accurately. **You may be eligible if...** - You have been diagnosed with stomach cancer or cancer at the junction of the stomach and esophagus confirmed by biopsy - You received chemotherapy before surgery (neoadjuvant chemotherapy) and then had surgery to remove the cancer - You had a CT scan, stomach scope, and biopsy before treatment began **You may NOT be eligible if...** - Your tumor was not clearly visible on CT scan due to poor stomach filling - Your biopsy sample did not have enough cancer cells for analysis - Your medical records or imaging data are incomplete Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNeoadjuvant chemotherapy with radical tumor resection surgery

All patients were pathologically diagnosed as advanced gastric cancer, all receive neoadjuvant chemotherapy, after the completion of neoadjuvant chemotherapy, all patients receive radical tumor resection surgery (partial gastrectomy or total gastrectomy, as proper).

Locations(1)

The Sixth Affiliated Hospital, Sun Yat-sen University

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06451393

Related Trials

Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis

NCT045579691 location

Lead-212 PSV359 Therapy for Patients With Solid Tumors

NCT067107567 locations

Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers

NCT028388361 location

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

NCT0671013281 locations

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

NCT0614703715 locations